Key Insights

Highlights

Treatment Research

2 treatments under study, led by Aef0217 100 Μg

Research Leaders

6 sponsors active, led by Pharmalex

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07334912Phase 2Recruiting

AEF0217 in Participants With Down Syndrome

Showing all 1 trials

Research Network

Common Treatments

  • Aef0217 100 Μg1
  • Aef0217 300 Μg1

Active Sponsors

  • Pharmalex1
  • European Commission1
  • BioClever 2005 S.L.1
  • Aelis Farma1
  • Eurofins ADME, S.L.1

Top Investigators

Related Conditions

  • Down Syndrome Trisomy 211

Activity Timeline